Where do we stand with hepatoblastoma? A review

Area of Science:

• Pediatric Oncology
• Hepatobiliary Malignancies
• Cancer Pathogenesis

Background:

• Hepatoblastoma (HB) is the most frequent primary liver tumor in children, accounting for about 1% of all pediatric cancers.
• Despite advances in treatment, challenges remain in staging and characterizing HB due to disparate systems.
• Current treatment combines surgery with neoadjuvant/adjuvant chemotherapy, significantly improving outcomes.

Purpose of the Study:

• To review the current understanding of Hepatoblastoma, including its characteristics, pathogenesis, and treatment.
• To highlight the impact of recent cell-biologic and molecular-biologic research on HB.
• To discuss future treatment directions, particularly for patients with poor prognoses.

Main Methods:

• Comprehensive literature review of Hepatoblastoma research.
• Analysis of clinical staging systems and histologic classifications.
• Synthesis of current knowledge on HB etiology, cytogenetics, and biology.

Main Results:

• Poor prognosis in HB is linked to large tumor size, multifocality, extrahepatic spread, and metastasis.
• Ongoing research into cytogenetic alterations and biologic features is advancing understanding of HB pathogenesis.
• New molecular insights are paving the way for novel therapeutic strategies.

Conclusions:

• Hepatoblastoma remains a complex pediatric liver malignancy requiring further research.
• Advances in understanding HB's molecular biology are crucial for developing improved treatments.
• Targeted therapies hold promise for enhancing outcomes in patients with advanced or aggressive HB.